1236356-58-3

Basic information

• Product Name: 4-amino-6-(4-{trans-4-[2-(4-methoxypiperidin-1-yl)-2-oxoethyl]cyclohexyl}phenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one
• Synonyms: 4-amino-6-(4-{trans-4-[2-(4-methoxypiperidin-1-yl)-2-oxoethyl]cyclohexyl}phenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one
• CAS NO: 1236356-58-3
• Molecular Weight: 493.606
• Mol File: 1236356-58-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-amino-6-(4-{trans-4-[2-(4-methoxypiperidin-1-yl)-2-oxoethyl]cyclohexyl}phenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-6-(4-{trans-4-[2-(4-methoxypiperidin-1-yl)-2-oxoethyl]cyclohexyl}phenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one(1236356-58-3)
• EPA Substance Registry System: 4-amino-6-(4-{trans-4-[2-(4-methoxypiperidin-1-yl)-2-oxoethyl]cyclohexyl}phenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one(1236356-58-3)

Safety Data

• Hazardous Substances Data: 1236356-58-3(Hazardous Substances Data)

Upstream product

• 4045-24-3 4-methoxypiperidine 
• 1109276-89-2 2-((1r,4r)-4-(4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid 

Relevant articles and documents

Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor

DGAT-1 is an enzyme that catalyzes the final step in triglyceride synthesis. mRNA knockout experiments in rodent models suggest that inhibitors of this enzyme could be of value in the treatment of obesity and type II diabetes. The carboxylic acid-based DGAT-1 inhibitor 1 was advanced to clinical trials for the treatment of type 2 diabetes, despite of the low passive permeability of 1. Because of questions relating to the potential attenuation of distribution and efficacy of a poorly permeable agent, efforts were initiated to identify compounds with improved permeability. Replacement of the acid moiety in 1 with an oxadiazole led to the discovery of 52, which possesses substantially improved passive permeability. The resulting pharmacodynamic profile of this neutral DGAT-1 inhibitor was found to be similar to 1 at comparable plasma exposures.